Jean-Yves Pierga

Treatment of malignant gliomas in the elderly.

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types.

Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial.

High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection.

Clinical utility of circulating tumor cells in metastatic breast cancer.

Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions.

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.

Circulating tumor cells in breast cancer.

Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

FISH-in-CHIPS: A Microfluidic Platform for Molecular Typing of Cancer Cells.

Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Circulating tumor cells: clinical validity and utility.

Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.

Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR.

Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer.

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.

Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma.